Mouad Hamzaoui
@nephrohamzaoui.bsky.social
Nephrologist, MD, PhD, Compiègne.
Dialysis, Nephrology, Endothelial dysfunction, ADPKD.
Dialysis, Nephrology, Endothelial dysfunction, ADPKD.
Reposted by Mouad Hamzaoui
Reposted by Mouad Hamzaoui
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
November 20, 2025 at 6:47 PM
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
Reposted by Mouad Hamzaoui
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 7, 2025 at 4:36 PM
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
Reposted by Mouad Hamzaoui
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
October 30, 2025 at 8:58 PM
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
Le CJN×CJHTA en force pour parler IA, HTA et Néphrologie : programme en🏅#SFNDT2025
October 9, 2025 at 12:22 PM
Le CJN×CJHTA en force pour parler IA, HTA et Néphrologie : programme en🏅#SFNDT2025
Le Dr Jonathan NICOLAS nous parle de sa mise en place de la pose des cathéter tunnelisé en hémodialyse 🔥 #SFNDT2025
October 8, 2025 at 9:55 AM
Le Dr Jonathan NICOLAS nous parle de sa mise en place de la pose des cathéter tunnelisé en hémodialyse 🔥 #SFNDT2025
A la #SFNDT2025 le Pr HALIMI nous improvise une conférence sur l'histoire de l'HTA 🤩
October 8, 2025 at 8:35 AM
A la #SFNDT2025 le Pr HALIMI nous improvise une conférence sur l'histoire de l'HTA 🤩
October 7, 2025 at 4:34 PM
Reposted by Mouad Hamzaoui
💬 Entraîner les étudiants aux ECOS de Néphrologie avec une IA conversationnelle : c’est désormais possible grâce à ECOSBot, un superbe outil créé par l’équipe Lilloise d’Aghiles Hamroun !
Très heureux d’y participé avec les externes marseillais
@sfndt.bsky.social
academic.oup.com/ckj/advance-...
Très heureux d’y participé avec les externes marseillais
@sfndt.bsky.social
academic.oup.com/ckj/advance-...
ECOSBot: A Multicenter Validation Study of a Generative AI Tool for OSCE-Based Nephrology Training
AbstractBackground. Developing diagnostic reasoning in nephrology is particularly challenging due to its pathophysiological complexity and reliance on abst
academic.oup.com
October 7, 2025 at 12:22 PM
💬 Entraîner les étudiants aux ECOS de Néphrologie avec une IA conversationnelle : c’est désormais possible grâce à ECOSBot, un superbe outil créé par l’équipe Lilloise d’Aghiles Hamroun !
Très heureux d’y participé avec les externes marseillais
@sfndt.bsky.social
academic.oup.com/ckj/advance-...
Très heureux d’y participé avec les externes marseillais
@sfndt.bsky.social
academic.oup.com/ckj/advance-...
Le congrès de la #SFNDT2025 est lancé ! IRA et immunothérapie : la place de la biopsie rénale reste primordial pour ajuster les traitements par @sabinekaram.bsky.social #SFNDT #TOURS
October 7, 2025 at 12:27 PM
Le congrès de la #SFNDT2025 est lancé ! IRA et immunothérapie : la place de la biopsie rénale reste primordial pour ajuster les traitements par @sabinekaram.bsky.social #SFNDT #TOURS
Reposted by Mouad Hamzaoui
KDIGO is pleased to announce the publication of the 2025 IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV) Guideline, along with its Executive Summary in @kidneyint.bsky.social.
Download: kdigo.co/KDIGO-IgAN-I...
Read in KI: kdigo.co/KDIGO-IgAN-I...
Exec Summary: kdigo.co/IgAN-IgAV-Gu...
Download: kdigo.co/KDIGO-IgAN-I...
Read in KI: kdigo.co/KDIGO-IgAN-I...
Exec Summary: kdigo.co/IgAN-IgAV-Gu...
September 18, 2025 at 10:34 AM
KDIGO is pleased to announce the publication of the 2025 IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV) Guideline, along with its Executive Summary in @kidneyint.bsky.social.
Download: kdigo.co/KDIGO-IgAN-I...
Read in KI: kdigo.co/KDIGO-IgAN-I...
Exec Summary: kdigo.co/IgAN-IgAV-Gu...
Download: kdigo.co/KDIGO-IgAN-I...
Read in KI: kdigo.co/KDIGO-IgAN-I...
Exec Summary: kdigo.co/IgAN-IgAV-Gu...
Reposted by Mouad Hamzaoui
Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD)
doi.org/10.1093/ckj/...
doi.org/10.1093/ckj/...
May 6, 2025 at 11:05 AM
Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD)
doi.org/10.1093/ckj/...
doi.org/10.1093/ckj/...
Reposted by Mouad Hamzaoui
Just published in NDT : #SGLT2i for patients with #ADPKD – closing the evidence gap
With experts from 🇩🇪🇳🇱🇯🇵🇺🇸🇫🇷 we review:
✅ Rationale for SGLT2i in ADPKD
✅ Preclinical and observational evidence
✅ Potential disease-specific benefits and risks
✅ Ongoing/upcoming trials, incl. #DAPAPKD & #STOPPKD
With experts from 🇩🇪🇳🇱🇯🇵🇺🇸🇫🇷 we review:
✅ Rationale for SGLT2i in ADPKD
✅ Preclinical and observational evidence
✅ Potential disease-specific benefits and risks
✅ Ongoing/upcoming trials, incl. #DAPAPKD & #STOPPKD
April 9, 2025 at 9:27 PM